William Mack & Associates’s Bristol-Myers Squibb BMY Stock Holding History

William Mack & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34.6K	Buy	+555	New	+$35.1K	0.01%	281

Other funds holding BMY

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Independent Franchise Partners London, United Kingdom $16.1B AUM 4.39% 1-Year Est. Return

William Mack & Associates's BMY Position: Q3 2026 in Review

William Mack & Associates opened a new position in Bristol-Myers Squibb (BMY) in Q3 2026: 555 shares worth $34.6K. The stake represents 0.01% of the portfolio and ranks #281 among its holdings.

2,253 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

William Mack & Associates held 555 shares of Bristol-Myers Squibb worth $34.6K as of Q3 2026.
Bristol-Myers Squibb was a new William Mack & Associates position in Q3 2026.
Bristol-Myers Squibb made up 0.01% of William Mack & Associates's portfolio in Q3 2026, its #281 holding.
2,253 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.